EDAP TMS Future Growth

Future criteria checks 1/6

EDAP TMS is forecast to grow earnings and revenue by 56.2% and 17.6% per annum respectively while EPS is expected to grow by 56.2% per annum.

Key information

56.2%

Earnings growth rate

56.2%

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	17.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Mar 22

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

Aug 24

EDAP's Focal One Revenue Is Set To Accelerate

Aug 08

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

Jul 19

Acceleration At EDAP

Jan 11

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Jan 06

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Nov 25

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Sep 07

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

Jun 15

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Apr 02

Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week

Jan 24

Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows

Jan 14

New reimbursement rules for HIFU technology to favor EDAP TMS

Dec 09

EDAP TMS S.A. EPS misses by $0.02, beats on revenue

Nov 18

Earnings and Revenue Growth Forecasts

NasdaqGM:EDAP - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	91	-5	N/A	N/A	2
12/31/2025	77	-10	N/A	N/A	3
12/31/2024	68	-13	N/A	N/A	3
12/31/2023	60	-21	-19	-15	N/A
9/30/2023	57	-21	-21	-17	N/A
6/30/2023	57	-17	-17	-13	N/A
3/31/2023	57	-11	-10	-7	N/A
12/31/2022	55	-3	-5	-3	N/A
9/30/2022	53	4	4	6	N/A
6/30/2022	51	3	3	5	N/A
3/31/2022	47	0	2	4	N/A
12/31/2021	44	1	3	4	N/A
9/30/2021	45	0	4	6	N/A
6/30/2021	45	0	N/A	N/A	N/A
3/31/2021	44	0	N/A	N/A	N/A
12/31/2020	42	-2	0	2	N/A
9/30/2020	38	-3	N/A	N/A	N/A
6/30/2020	39	-2	N/A	N/A	N/A
3/31/2020	42	0	N/A	N/A	N/A
12/31/2019	45	2	2	4	N/A
9/30/2019	46	4	N/A	N/A	N/A
6/30/2019	44	2	N/A	N/A	N/A
3/31/2019	40	0	N/A	N/A	N/A
12/31/2018	39	0	-2	0	N/A
9/30/2018	36	-1	N/A	N/A	N/A
6/30/2018	35	-1	-3	0	N/A
3/31/2018	36	-2	N/A	N/A	N/A
12/31/2017	36	-1	-5	-3	N/A
9/30/2017	36	-2	N/A	N/A	N/A
6/30/2017	37	0	N/A	-4	N/A
3/31/2017	36	4	N/A	N/A	N/A
12/31/2016	36	4	N/A	1	N/A
9/30/2016	37	10	N/A	N/A	N/A
6/30/2016	35	4	N/A	4	N/A
3/31/2016	35	2	N/A	N/A	N/A
12/31/2015	32	-2	N/A	1	N/A
9/30/2015	27	-9	N/A	N/A	N/A
6/30/2015	27	2	N/A	-1	N/A
3/31/2015	25	-4	N/A	N/A	N/A
12/31/2014	26	-1	N/A	-1	N/A
9/30/2014	28	2	N/A	N/A	N/A
6/30/2014	27	-5	N/A	-1	N/A
3/31/2014	26	0	N/A	N/A	N/A
12/31/2013	24	-5	N/A	-2	N/A
9/30/2013	25	-6	N/A	N/A	N/A
6/30/2013	25	-6	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EDAP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EDAP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EDAP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EDAP's revenue (17.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: EDAP's revenue (17.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time

EDAP TMS Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

Price target increased by 12% to US$14.50

Consensus EPS estimates increase by 36%

Consensus EPS estimates have been upgraded

Recent updates

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Acceleration At EDAP

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020)

Price target decreased to US$11.50

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP).

Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020)

EDAP TMS S.A. Provides Unaudited Earnings Guidance for the Second Quarter of 2021

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

First quarter 2021 earnings released: EPS €0.026 (vs €0.045 loss in 1Q 2020)